New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
16 Mai 2024 - 1:00PM
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a
clinical-stage biopharmaceutical company focused on delivering
groundbreaking therapies using its lipid nanocrystal (LNC) platform
delivery technology, announces new in vitro data showing the use of
LNCs for the delivery of small oligonucleotides was presented
yesterday in a poster session at TIDES USA 2024: Oligonucleotide
& Peptide Therapeutics, a hybrid in-person and virtual
conference underway in Boston.
The poster, “Intracellular Delivery of Small
Oligonucleotides with Lipid Nanocrystals (LNCs): in vitro studies,”
was presented by Hui Liu, PhD, Chief Technology Officer of Matinas,
and is available here. The poster discusses in vitro
studies demonstrating the avid uptake of LNC formulations of
various cytokine-targeted small oligonucleotides in murine
macrophages, with up to 70% gene knockdown observed for each
targeted cytokine.
“There has been heightened interest in small
oligonucleotides in multiple therapeutic areas, yet a major barrier
to their use is systemic delivery, which can lead to toxicity and
adverse immunogenicity,” said Dr. Liu. “These in vitro studies
showed that our LNCs can successfully encapsulate and protect ASOs,
siRNA and other small oligonucleotides even when exposed to gastric
fluid and can deliver them to a variety of cells with demonstrable
biological activity. These characteristics make LNCs a highly
promising oral drug delivery platform for future applications
requiring oral delivery of small oligonucleotides.”
About Matinas BioPharmaMatinas
BioPharma is a biopharmaceutical company focused on delivering
groundbreaking therapies using its lipid nanocrystal (LNC) platform
delivery technology.
Matinas’ lead LNC-based therapy is MAT2203, an
oral formulation of the broad-spectrum antifungal drug amphotericin
B, which although highly potent, can be associated with significant
toxicity. Matinas’ LNC platform provides oral delivery of
amphotericin B without the significant nephrotoxicity otherwise
associated with IV-delivered formulations. Combining comparable
fungicidal activity with targeted delivery results in a lower risk
of toxicity and potentially creates the ideal antifungal agent for
the treatment of invasive fungal infections. MAT2203 was
successfully evaluated in the completed Phase 2 EnACT study in HIV
patients suffering from cryptococcal meningitis, meeting its
primary endpoint and achieving robust survival. MAT2203 will be
further evaluated in a single Phase 3 registration trial (the
“ORALTO” trial) as an oral step-down monotherapy following
treatment with AmBisome® (liposomal amphotericin B) compared with
the standard of care in patients with invasive aspergillosis who
have limited treatment options.
In addition to MAT2203, preclinical and clinical
data have demonstrated that this novel technology can potentially
provide solutions to many challenges of achieving safe and
effective intracellular delivery of both small molecules and
larger, more complex molecular cargos including small
oligonucleotides such as ASOs and siRNA. The combination of its
unique mechanism of action and flexibility with routes of
administration (including oral) positions Matinas’ LNC technology
to potentially become a preferred next-generation orally available
intracellular drug delivery platform. For more information, please
visit www.matinasbiopharma.com.
Forward-looking StatementsThis
release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including
those relating to our business activities, our strategy and plans,
the future development of our product candidates, including
MAT2203, the Company’s ability to identify and pursue development,
licensing and partnership opportunities for our products, including
MAT2203, or platform delivery technology on favorable terms, if at
all, and the ability to obtain required regulatory approval and
other statements that are predictive in nature, that depend upon or
refer to future events or conditions. All statements other than
statements of historical fact are statements that could be
forward-looking statements. Forward-looking statements include
words such as "expects," "anticipates," "intends," "plans,"
"could," "believes," "estimates" and similar expressions. These
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to continue as a going concern, our ability to obtain additional
capital to meet our liquidity needs on acceptable terms, or at all,
including the additional capital which will be necessary to
complete the clinical trials of our product candidates; our ability
to successfully complete research and further development and
commercialization of our product candidates; the uncertainties
inherent in clinical testing; the timing, cost and uncertainty of
obtaining regulatory approvals; our ability to protect the
Company’s intellectual property; the loss of any executive officers
or key personnel or consultants; competition; changes in the
regulatory landscape or the imposition of regulations that affect
the Company’s products; and the other factors listed under "Risk
Factors" in our filings with the SEC, including Forms 10-K, 10-Q
and 8-K. Investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this release. Except as may be required by law, the Company does
not undertake any obligation to release publicly any revisions to
such forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events. Matinas BioPharma’s product candidates are all in a
development stage and are not available for sale or use.
Investor ContactLHA Investor
RelationsJody Cain Jcain@lhai.com 310-691-7100
Matinas Biopharma (AMEX:MTNB)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Matinas Biopharma (AMEX:MTNB)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024